#United States #Salt Lake City #Co-Diagnostics #PCR Testing #Vector Smart

Co-Diagnostics Expands Its Vector Smart Division

Co-Diagnostics, Inc. (Nasdaq: CODX), a notable entity in the field of molecular diagnostics, has made significant strides in its Vector Smart division, broadening its reach to include mosquito abatement districts (MAD) across 21 states. This expansion comes at a crucial time, coinciding with the company's initiative to host a webinar aimed at attracting prospective customers in commemoration of National Mosquito Control Awareness Week. The growth includes the recent addition of four full laboratory installations in June 2026 alone.

According to CEO Dwight Egan, the surge in customer acquisitions underscores the efficacy of the company's proprietary technology and reflects an escalating need for monitoring vector-borne diseases. Co-Diagnostics aims to enable MADs with PCR tests that facilitate in-house testing, thereby decentralizing and streamlining mosquito surveillance.

The significance of this development cannot be overstated: the World Health Organization notes that vector-borne diseases, predominantly transmitted by mosquitoes, account for over 700,000 deaths each year. For instance, Maricopa County, Arizona reported its first West Nile virus-related death this season in June 2026. The Vector Smart products from Co-Diagnostics encompass multiplex PCR tests for major diseases such as West Nile, Zika, and dengue. These tests are specifically designed to enhance MADs’ situational awareness and improve the efficiency of their abatement strategies.

Egan further elaborated on the advantages of decentralizing PCR testing. By bringing testing capabilities directly to where they are needed, Co-Diagnostics intends to enhance rapid data acquisition for vector surveillance, paving the way for better coordination between public health agencies. Given the migratory nature of disease-carrying mosquitoes, timely collaboration and the sharing of surveillance data are pivotal for community protection efforts.

The company remains steadfast in its commitment to innovation, not only in the realm of decentralized PCR for vector control but also in the broader context of infectious disease diagnostics worldwide. Co-Diagnostics continues to pursue advanced applications of its unique testing technology to address the evolving landscape of public health challenges.

About Co-Diagnostics, Inc.

Co-Diagnostics, Inc. is a molecular diagnostics corporation based in Utah that develops, manufactures, and markets cutting-edge diagnostic technologies. Utilizing a patented platform, the company specializes in molecular tests that encompass DNA and RNA detection and analysis, catering to various health applications. In addition to its PCR capabilities, Co-Diagnostics also develops genetic markers that can be used in multiple diagnostic contexts beyond infectious diseases.

Looking Forward

With its expanded presence and innovative solutions, Co-Diagnostics is poised to lead the charge in addressing vector-borne diseases effectively. The company's proactive initiatives signal a greater awareness and readiness to confront emerging public health issues, ensuring healthier environments for communities at risk.